A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

To join this study, you need to be an adult between 18 and 60 years old and have been diagnosed with a type of MS called relapsing MS (this includes relapsing-remitting MS or secondary progressive MS with relapses).

Your MS should show some signs of recent activity. This means you would have had at least one relapse in the last year, or two relapses in the last two years, or have shown recent signs of MS activity on a brain scan (MRI) within the last six months. Also, your MS should not be too severe, meaning your disability score (known as EDSS) should be 5.5 or less.

There are also some reasons why you might not be able to join. For example, if you have primary progressive MS or secondary progressive MS without relapses, or if you have a different condition called neuromyelitis optica spectrum disorder. If you've had a relapse very recently (within the last 30 days) or have a very large number of active lesions on your MRI scan, you also wouldn't be able to take part.

If you decide to take part in the study, it will involve several stages over about 92 weeks (approximately 1 year and 9 months). First, there's a screening period to check if the study is right for you.

For the first 12 weeks, you'll receive weekly injections under the skin (like a small jab) of either obexelimab or a placebo. You won't know which one you're getting. After this, for the next 12 weeks, every participant will receive weekly injections of obexelimab. Following these 24 weeks, you'll continue to receive obexelimab for about a year.

Throughout the study, you'll have regular visits to the clinic for check-ups, assessments, and to receive your medication. There will also be a follow-up period after your last dose of medicine to monitor your health. You may need to visit the clinic more often during this follow-up if special blood tests haven't returned to normal levels. The study team will explain everything in detail if you are interested.